MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2025 International Congress

    Course of Impulse Control Disorder in People Living with Parkinson’s Disease: A Longitudinal Study on Dopamine Agonist Treatment

    D. Náfate Wences, AE. Lopez Lobato, AJ. Hernández Medrano, AG. Cervantes Arriaga, M. Rodríguez Violante (Mexico City, Mexico)

    Objective: To compare the incidence and severity of ICDs among PwP treated with different DA, specifically examining their respective impacts on ICD onset and remission.…
  • 2025 International Congress

    Dopa-Responsive Parkinsonism Secondary to Tauopathy: Clinical, Pathological, and Genetic Study

    S. Giri Ravindran, B. Daud Shah, E. Noyes, V. Zherebitskiy, A. Rajput, M. Farrer, A. Rajput (Saskatoon, Canada)

    Objective: To report on the clinical, pathological, and genetic findings of four cases of levodopa-responsive parkinsonism with long survival and tauopathy. Background: The most common…
  • 2025 International Congress

    A Novel Dopaminergic Modulator (NDM-101) as an Adjunct to Levodopa: Enhancing Motor Control Without Worsening Dyskinesia in Parkinson’s Disease

    F. Al-Zaidi (Almaty, Kazakhstan)

    Objective: To evaluate the efficacy and safety of NDM-101 as an adjunct to levodopa in reducing OFF-time, improving motor function, and maintaining quality of life…
  • 2024 International Congress

    AI for Personalized Medication Management in Parkinson’s Disease

    R. Diaz-Rincon, H. Khoshbouei, B. Shickel (Gainesville, USA)

    Objective: To assess medication usage over time in Parkinson’s Disease utilizing AI in EHR data. Background: Parkinson's disease (PD) is a complex neurodegenerative disorder characterized…
  • 2024 International Congress

    Dopamine Dysregulation in Parkinson’s Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line

    J. Hall, R. Islam, D. Nolasco, B. Carr (GAINESVILLE, USA)

    Objective: Parkinson's Disease (PD) inherently disrupts dopaminergic transmission, primarily within the nigrostriatal pathway, necessitating dopaminergic therapies. However, these therapies can lead to Dopamine Dysregulation Syndrome…
  • 2024 International Congress

    Resting state EEG source analysis identifies distinct neural signature associated with impulse control disorders in PD

    E. Iglesias-Camacho, FJ. Gómez Campos, P. Franco Rosado, L. Garrote Espina, AM. Castellano-Gerrero, M. San Eufrasio, C. Perez-Calvo, L. Muñoz-Delgado, S. Jesús, D. Macías-García, E. Ojeda-Lepe, A. Adarmes-Gómez, F. Carrillo, JF. Martín-Rodriguez, P. Mir (Seville, Spain)

    Objective: To identify EEG source level differences between patients with Parkinson's disease (PD) and associated impulse control disorders (ICD) and patients without ICD. Background: Previous…
  • 2024 International Congress

    Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.

    D. Ortiz-Zacarias, S. Castillo-Torres, M. Cansino-Torres, J. Trejo-Ayala, B. Chávez-Luevanos, I. Estrada-Bellmann (Monterrey, Mexico)

    Objective: To describe the clinical and demographic characteristics of patients with PDP and their relationship with the use of DAs. Background: Parkinson’s Disease Psychosis (PDP)…
  • 2024 International Congress

    In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease

    C. Mahapatra (Mumbai, India)

    Objective: Recent experimental evidence suggests a potential interaction between dopamine D2 receptors (D2R) and N-type Ca2+ channels, impacting the firing patterns of Subthalamic neuronal (STN)…
  • 2024 International Congress

    Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson’s disease in the low-income country and environment of restricted medications.

    B. Mukhammedaminov (Uzbekistan, Uzbekistan)

    Objective: To inform the world community about the state situation on Parkinson’s disease in Uzbekistan. Objective: To Co inform the world community about the state…
  • 2024 International Congress

    Medication Refractory Restless Legs Syndrome: Real-World Experience

    P. Petramfar, J. Jankovic (Houston, USA)

    Objective: To identify demographic or clinical factors predictive of refractory cases. Background: Restless Legs Syndrome (RLS), impacting 5-13% of the US population, poses challenges in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Comorbid Normal Pressure Hydrocephalus with Parkinson’s disease: a call for clinical awareness
  • Clonazepam as a cure or a cause? : Withdrawal Emergent Syndrome
  • Common mistakes in the MoCA test in patients with Parkinson’s Disease in Kyrgyzstan
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley